Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.

@article{Lasser2004EfficacyAS,
  title={Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.},
  author={Robert A. Lasser and Cynthia A. Bossie and Young Zhu and Georges M Gharabawi and Mari{\"e}lle Eerdekens and Michael Davidson},
  journal={International journal of geriatric psychiatry},
  year={2004},
  volume={19 9},
  pages={898-905}
}
BACKGROUND Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long-acting risperidone, the first long-acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. OBJECTIVE To assess the efficacy and safety of long-acting injectable risperidone in elderly patients with psychotic disorders. METHODS This is a subanalysis of 57 patients aged > or =65 years enrolled in an open-label study of long-acting… CONTINUE READING